Local Control in Metastatic Neuroblastoma in Children over 1 Year of Age

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2015 Apr 18

PMID 25886486

Citations 12

Authors

Maria Antonietta De Ioris

Alessandro Crocoli

Benedetta Contoli

Maria Carmen Garganese

Gianluigi Natali

Paolo Toma

Alessandro Jenkner

Renata Boldrini

Maria Debora De Pasquale

Giuseppe Maria Milano

Silvia Madafferi

Aurora Castellano

Franco Locatelli

Alessandro Inserra

Affiliations

Soon will be listed here.

Abstract

Background: Local control is always considered in metastatic neuroblastoma (NBL). The aim of this study is to evaluate the impact of radical surgery on survival in children over 1 year of age.

Methods: Fifty-eight patients older than 1 year of age with metastatic NBL were treated with conventional plus high-dose chemotherapy with or without addition of local radiotherapy (RT, 21Gy). Surgery was classified as radical surgery (complete resection and gross total resection) or non-radical surgery. The Kaplan-Meier method and the Cox proportional hazard model were used to calculate the probability of progression free and overall survival (PFS and OS) and for multivariate analysis.

Results: The 5-year PFS and OS for patients with radical surgery were 26% (95% CI 14-40%) and 38% (95% CI 23-53%) respectively, while the PFS and OS for patients without radical surgery were 33% (95% CI 10-59%) and 31% (95% CI 10-55%) (respectively, P 0.85 and P 0.42). The 5-year PFS and OS for patients who received RT were 36% (95% CI 19-53%) and 46% (95% CI 26-64%) respectively, while the 5-year PFS and OS for patients who did not receive RT were 22% (95% CI 9-38%) and 27% (95% CI 13-42%) respectively (P 0.02 for PFS). Multivariate analysis confirmed the role of well-known prognostic factors, such as the presence of MYCN amplification, age and response before high-dose chemotherapy.

Conclusions: Our data suggest that the degree of resection does not influence survival in metastatic NBL patients treated with high-dose chemotherapy; local RT contributes to local disease control.

Citing Articles

Isolated central nervous system relapses in patients with high-risk neuroblastoma -clinical presentation and prognosis: experience of the Polish Paediatric Solid Tumours Study Group.

Wieczorek A, Stefanowicz J, Hennig M, Adamkiewicz-Drozynska E, Stypinska M, Dembowska-Baginska B BMC Cancer. 2022; 22(1):701.

PMID: 35752779 PMC: 9233790. DOI: 10.1186/s12885-022-09776-x.

International Society of Paediatric Surgical Oncology (IPSO) Surgical Practice Guidelines.

Abib S, Chui C, Cox S, Abdelhafeez A, Fernandez-Pineda I, Elgendy A Ecancermedicalscience. 2022; 16:1356.

PMID: 35510137 PMC: 9023308. DOI: 10.3332/ecancer.2022.1356.

Roles of Surgery in the Treatment of Patients With High-Risk Neuroblastoma in the Children Oncology Group Study: A Systematic Review and Meta-Analysis.

Qi Y, Zhan J Front Pediatr. 2021; 9:706800.

PMID: 34722415 PMC: 8548868. DOI: 10.3389/fped.2021.706800.

Treatment and outcomes of high-risk neuroblastoma in Southeast Asia: a single-institution experience and review of the literature.

Lee A, Chui C, Kwok R, Lee K, Fong C, Wong W Singapore Med J. 2021; 64(5):319-325.

PMID: 34688228 PMC: 10219116. DOI: 10.11622/smedj.2021164.

Dosimetric comparison of tomotherapy and volumetric-modulated arc therapy for children with neuroblastoma.

Liu X, Liu Z, Pang T, Dong T, Qiu J Pediatr Investig. 2020; 4(3):186-191.

PMID: 33150312 PMC: 7520106. DOI: 10.1002/ped4.12215.

References

Kushner B, Wolden S, LaQuaglia M, Kramer K, Verbel D, Heller G . Hyperfractionated low-dose radiotherapy for high-risk neuroblastoma after intensive chemotherapy and surgery. J Clin Oncol. 2001; 19(11):2821-8. DOI: 10.1200/JCO.2001.19.11.2821. View

Stainsby D, MacLennan S, Thomas D, Isaac J, Hamilton P . Guidelines on the management of massive blood loss. Br J Haematol. 2006; 135(5):634-41. DOI: 10.1111/j.1365-2141.2006.06355.x. View

Pearson A, Pinkerton C, Lewis I, Imeson J, Ellershaw C, Machin D . High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. Lancet Oncol. 2008; 9(3):247-56. DOI: 10.1016/S1470-2045(08)70069-X. View

Monclair T, Brodeur G, Ambros P, Brisse H, Cecchetto G, Holmes K . The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol. 2008; 27(2):298-303. PMC: 2650389. DOI: 10.1200/JCO.2008.16.6876. View

Matthay K, Reynolds C, Seeger R, Shimada H, Adkins E, Haas-Kogan D . Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. J Clin Oncol. 2009; 27(7):1007-13. PMC: 2738615. DOI: 10.1200/JCO.2007.13.8925. View

Sultan I, Ghandour K, Al-Jumaily U, Hashem S, Rodriguez-Galindo C . Local control of the primary tumour in metastatic neuroblastoma. Eur J Cancer. 2009; 45(10):1728-32. DOI: 10.1016/j.ejca.2009.04.021. View

Robbins J, Krasin M, Pai Panandiker A, Watkins A, Wu J, Santana V . Radiation therapy as part of local control of metastatic neuroblastoma: the St Jude Children's Research Hospital experience. J Pediatr Surg. 2010; 45(4):678-86. PMC: 2897834. DOI: 10.1016/j.jpedsurg.2009.11.003. View

De Ioris M, Castellano A, Ilari I, Garganese M, Natali G, Inserra A . Short topotecan-based induction regimen in newly diagnosed high-risk neuroblastoma. Eur J Cancer. 2010; 47(4):572-8. DOI: 10.1016/j.ejca.2010.10.023. View

Zwaveling S, Tytgat G, van der Zee D, Wijnen M, Heij H . Is complete surgical resection of stage 4 neuroblastoma a prerequisite for optimal survival or may >95 % tumour resection suffice?. Pediatr Surg Int. 2012; 28(10):953-9. PMC: 3445800. DOI: 10.1007/s00383-012-3109-3. View

10.

De Ioris M, Contoli B, Jenkner A, Pasquale M, Serra A, De Sio L . Comparison of two different conditioning regimens before autologous transplantation for children with high-risk neuroblastoma. Anticancer Res. 2012; 32(12):5527-33. View

11.

Simon T, Haberle B, Hero B, von Schweinitz D, Berthold F . Role of surgery in the treatment of patients with stage 4 neuroblastoma age 18 months or older at diagnosis. J Clin Oncol. 2013; 31(6):752-8. DOI: 10.1200/JCO.2012.45.9339. View

12.

Castel V, Tovar J, Costa E, Cuadros J, Ruiz A, Rollan V . The role of surgery in stage IV neuroblastoma. J Pediatr Surg. 2002; 37(11):1574-8. DOI: 10.1053/jpsu.2002.36187. View

13.

von Schweinitz D, Hero B, Berthold F . The impact of surgical radicality on outcome in childhood neuroblastoma. Eur J Pediatr Surg. 2003; 12(6):402-9. DOI: 10.1055/s-2002-36952. View

14.

Haas-Kogan D, Swift P, Selch M, Haase G, Seeger R, Gerbing R . Impact of radiotherapy for high-risk neuroblastoma: a Children's Cancer Group study. Int J Radiat Oncol Biol Phys. 2003; 56(1):28-39. DOI: 10.1016/s0360-3016(02)04506-6. View

15.

La Quaglia M, Kushner B, Su W, Heller G, Kramer K, Abramson S . The impact of gross total resection on local control and survival in high-risk neuroblastoma. J Pediatr Surg. 2004; 39(3):412-7. DOI: 10.1016/j.jpedsurg.2003.11.028. View

16.

Donfrancesco A, Jenkner A, Castellano A, Ilari I, Milano G, De Sio L . Ifosfamide/carboplatin/etoposide (ICE) as front-line, topotecan/cyclophosphamide as second-line and oral temozolomide as third-line treatment for advanced neuroblastoma over one year of age. Acta Paediatr Suppl. 2004; 93(445):6-11. DOI: 10.1111/j.1651-2227.2004.tb03048.x. View

17.

Adkins E, Sawin R, Gerbing R, London W, Matthay K, Haase G . Efficacy of complete resection for high-risk neuroblastoma: a Children's Cancer Group study. J Pediatr Surg. 2004; 39(6):931-6. DOI: 10.1016/j.jpedsurg.2004.02.041. View

18.

Brodeur G, Pritchard J, Berthold F, Carlsen N, Castel V, Castelberry R . Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993; 11(8):1466-77. DOI: 10.1200/JCO.1993.11.8.1466. View

19.

La Quaglia M, Kushner B, Heller G, Bonilla M, Lindsley K, Cheung N . Stage 4 neuroblastoma diagnosed at more than 1 year of age: gross total resection and clinical outcome. J Pediatr Surg. 1994; 29(8):1162-5; discussion 1165-6. DOI: 10.1016/0022-3468(94)90301-8. View

20.

Matthay K, Villablanca J, Seeger R, Stram D, Harris R, Ramsay N . Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med. 1999; 341(16):1165-73. DOI: 10.1056/NEJM199910143411601. View